Reuters Health News Summary
• Xenon Pharmaceuticals paused new patient enrollment in clinical trials for its experimental major and bipolar depression drug on Thursday. • The company halted the studies following reports of side effects related to the mental and nervous system. • Xenon shares fell more than 25% in after-hours trading as a result of the trial pause.
bundle.app